What Neurosom™ does

Neurosom is an Oregon-based neurotechnology company developing a closed-loop sleep therapy platform centered on its Sleep WISP wearable headband. The device combines high-density EEG measurement with transcranial electrical stimulation (TES) and is driven by NEAT, the company's FDA 510(k)-cleared AI sleep-staging software built on a convolutional neural network trained on multi-site polysomnography datasets. The system's intended mechanism is to identify deep (N3) sleep in real time and deliver precisely timed, painless electrical stimulation to extend and enhance deep sleep, thereby supporting glymphatic clearance and reducing dementia risk. Additional products include SOURCERER, an FDA 510(k)-cleared EEG source-localization software developed by parent/partner BEL, which is integrated within BEL's FLOW EEG/ERP informatics platform.

The company is positioned at the intersection of consumer sleep technology and clinical neurotech. Its GTM motion is sales-led and B2B, relying on key opinion leader clinical sites — Mount Sinai, Wake Forest, Oregon Health & Science University, Northwestern, and the Sleep and Brain Clinic — for clinical trials and research deployments. Revenue streams are anticipated across Sleep WISP hardware sales, NEAT/SOURCERER software licensing or subscription, and clinical-trial/research-services work; current cash inflows are dominated by non-dilutive grants including a $2.5M National Institute on Aging Phase II award for a Mild Cognitive Impairment trial and prior Department of Defense funding that seeded the technology. Pricing is not publicly disclosed, and the company is not yet in scaled commercial distribution. Neurosom has raised a $5M Seed Round and an oversubscribed bridge round led by Portland Seed Fund's Intrepid Oregon Fund, and is advancing toward a priced Seed Round in the first half of 2026.

Neurosom operates as a partner company to BEL (The Brain Electrophysiology Laboratory Company), with leadership drawn heavily from the founder team of Electrical Geodesics (EGI) — sold to Philips in 2017 after being listed on the London Stock Exchange — providing deep domain expertise in dense-array EEG. The company holds at least three issued US patents covering neural oscillation desynchronization, geodesic sensor nets, and Bayesian super-resolution EEG source analysis, with additional applications pending in glymphatic/ECS monitoring. Strategic momentum in 2025–2026 has been concentrated in regulatory (two FDA 510(k) clearances), clinical validation (peer-reviewed SLEEP Journal publications, Mount Sinai Parkinson's program), and capital formation rather than commercial revenue scaling.

Name

Neurosom™

Legal name

Neurosom

Website

https://neurosom.net

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Neurosom is an Oregon-based neurotechnology company developing the Sleep WISP wearable and FDA-cleared NEAT AI sleep-staging software to deliver closed-loop, at-home EEG-guided transcranial stimulation aimed at extending deep sleep and reducing dementia risk. Its primary customers today are clinical KOL sites and academic research institutions running sleep and neurodegeneration trials.

Ownership category

akta.pro rank

Product category

Sleep Therapy Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB)

Keywords

• Sleep therapy devices
• EEG brain monitoring
• Neuromodulation technology
• Transcranial electrical stimulation
• Sleep staging software

Headquarters

HQ city

Eugene

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Sleep WISP Wearable Device Sales: Sale of the Sleep WISP wearable EEG/TES headband hardware, applied by users at home for sleep therapy. The device is the core physical product enabling the company's sleep improvement and brain health platform.
2. NEAT AI Software Licensing / Subscription: FDA-cleared NEAT AI-powered sleep staging software powers the Sleep WISP in real time and can be used independently for clinical EEG sleep assessment. The software is integrated into the device platform and available for clinical practice/laboratory integration, likely through licensing or subscription.
3. SOURCERER Software Licensing: FDA 510(k)-cleared source localization software, managed by FLOW platform, available as standalone or integrated with BEL EEG System One — offered as a licensed software tool for clinical and research EEG analysis.
4. Clinical Trial and Research Partnerships: Revenue from government-funded clinical trials, including NIA Phase II funding for MCI study and DoD-funded development of Sleep WISP for active-duty service members.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Neurosom develops the Sleep WISP, a wearable EEG/tES headband worn at home during sleep, paired with its FDA-cleared NEAT AI-powered sleep staging software to track sleep cycles in real time and deliver closed-loop, painless electrical stimulation that extends deep (N3) sleep and supports glymphatic clearance to reduce dementia risk. The company also distributes the FDA-cleared SOURCERER EEG source localization software for clinical and research EEG analysis. Customers include older adults seeking sleep and cognitive health benefits, sleep medicine and neurology clinicians, and academic research institutions running clinical trials.

Product overview

Neurosom delivers a unified platform for personalized brain health and sleep therapy. The core portfolio consists of two integrated products: Sleep WISP (a wearable EEG/TES headband for at-home sleep therapy) and NEAT (FDA-cleared AI-powered sleep staging software). NEAT serves as the intelligent foundation—it classifies sleep stages in real time and powers Sleep WISP's closed-loop stimulation to extend deep sleep. A third product, SOURCERER (developed by partner BEL), provides FDA-cleared EEG source localization. The platform targets dementia risk reduction through glymphatic clearance optimization, with clinical trials for Mild Cognitive Impairment funded by the National Institute on Aging.

Differentiator

Problem solved

Functional benefit

Brands

• Sleep WISP: A wearable EEG/tES sleep therapy headband applied at home, built to boost cognitive health. AI-powered NEAT software tracks sleep stages in real time, signals gentle stimulation to lengthen deep sleep, and provides personalized treatment to improve clearance of brain metabolic waste.
• NEAT (Neurosom EEG Assessment Technology)

Products and services

• Sleep WISP® A wearable EEG/tES (transcranial electrical stimulation) sleep therapy headband applied by the user at home during sleep; uses AI-powered NEAT software to track sleep cycles in real time and deliver painless electrical stimulation to extend deep sleep and support brain metabolic waste clearance, targeting dementia risk reduction in adults including those with MCI and Parkinson's disease.
• NEAT (Neurosom EEG Assessment Technology) FDA 510(k)-cleared AI-powered automatic sleep staging software using a deep neural network trained on multi-site PSG datasets to deliver AASM-compliant hypnograms and sleep statistics without requiring ECG, EOG, or EMG; powers the Sleep WISP therapy system and is available for clinical EEG sleep assessment in sleep medicine and neurology practices.
• SOURCERER FDA 510(k)-cleared EEG source localization software providing in-depth visual examination of brain activity; available as a standalone tool or integrated with the BEL EEG System One, managed within the FLOW database and informatics platform.

Quantifiable outcome

• Extends N3 (deep) sleep duration and improves REM sleep through targeted tES stimulation at the N2-N3 transition
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• Icahn School of Medicine at Mount SinaicoreStrategic or Co-development Partner · 1 January 2026Mount Sinai is a key research partner conducting studies on Parkinson's disease and Sleep WISP therapy. Dr. Allison C. Waters (Director, Waters Lab, Nash Family Center for Advanced Circuit Therapeutics) and Dr. Joohi Jimenez-Shahed lead a second Parkinson's disease study funded by the Glickenhaus Research Scholar Award. A multidisciplinary clinical team including Dr. Emmanuel During and Dr. Rachel Fremont is involved.
• BEL (The Brain Electrophysiology Laboratory Company)coreTechnology or IntegrationBEL is the parent/partner company of Neurosom, co-founded by Dr. Don Tucker. BEL pursues advanced R&D in brain electrophysiological assessment and therapy and has developed key technologies licensed to or shared with Neurosom, including SOURCERER (FDA-cleared) and NEAT (FDA-cleared) software. BEL was founded in 2018 after the sale of EGI to Philips. Neurosom and BEL collaborate on technology development, regulatory filings, and scientific publications. BEL manages the FLOW platform which optimizes SOURCERER software.
• Sleep and Brain CliniccoreStrategic or Co-development PartnerPartnership with Sleep and Brain Clinic in Menlo Park, California for a new clinical trial using the Sleep WISP. Dr. Anil Rama, Founder of Sleep and Brain Clinic, is a user of Neurosom's advanced EEG technology and has provided a testimonial endorsing the Sleep WISP therapy's scientific rigor and clinical promise.
• Oregon Health and Science University (OHSU)supportingStrategic or Co-development PartnerOHSU is one of the KOL sites using the Sleep WISP. Dr. Miranda Lim, M.D., Ph.D. from OHSU co-authored the SLEEP Journal paper on tES stimulation effects on N3 and REM sleep.
• Wake Forest UniversitysupportingStrategic or Co-development PartnerWake Forest University School of Medicine, specifically Dr. Ruth Benca (Chair, Department of Psychiatry and Human Behavior), collaborates with Neurosom on webinars and research related to glymphatic clearance and sleep aging. Dr. Benca presented at Neurosom's June 2026 webinar on glymphatic clearance.
• Northwestern UniversitysupportingStrategic or Co-development PartnerNorthwestern University is listed as one of the KOL clinical sites using the Sleep WISP for sleep and brain health research.
• University of Kansas Medical Center / Hoglund Biomedical Imaging CentersupportingStrategic or Co-development PartnerDr. Swati Levendovszky, Associate Professor of Radiology at University of Kansas Medical Center and Director of the Hoglund Biomedical Imaging Center, presented MRI findings on cerebral fluid content and flow at Neurosom's June 2026 glymphatic clearance webinar.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NeuroPace: NeuroPace makes the RNS System, an implanted closed-loop neurostimulator for epilepsy. It is comparable to Neurosom in applying closed-loop EEG-triggered electrical stimulation, but in an implantable form factor targeting refractory epilepsy rather than at-home sleep.
• Muse: Muse makes consumer EEG headbands for meditation and sleep, using brain-sensing signals to deliver biofeedback. Comparable to Neurosom in EEG-headband form factor and consumer-brain-tech category, though focused on meditation rather than deep-sleep neuromodulation.
• Dreem: Dreem (formerly Rythm) develops EEG-based wearable headbands for sleep monitoring and enhancement. It is the most direct competitor to Neurosom's Sleep WISP, using EEG to track sleep architecture and applying auditory or electrical stimulation in a closed-loop format.
• Compumedics: Compumedics manufactures clinical PSG and home sleep testing devices with EEG-based sleep diagnostics. It is comparable to Neurosom's NEAT software offering in clinical sleep staging, though its primary hardware business is full PSG labs rather than consumer wearables.
• Neuronetics: Neuronetics makes transcranial magnetic stimulation (TMS) systems for depression. It is comparable to Neurosom as a neurostimulation device company with FDA clearance and an outpatient/clinical-channel business model serving neurological conditions.
• electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS) devices for neurological and respiratory conditions. It is comparable to Neurosom as a non-invasive electrical-neuromodulation company with FDA-cleared therapeutic claims and a similar regulatory pathway.

Emerging players

• Kernel: Kernel develops wearable brain-sensing devices (Kernel Flux, Kernel Flow) using optical and EEG modalities for cognitive monitoring. It overlaps with Neurosom in applying advanced neurotech to consumer brain-health, though focused on cognitive performance metrics rather than sleep therapy.

Broad incumbents

• ResMed: ResMed is a global leader in sleep medicine, primarily through CPAP devices for sleep apnea and digital health platforms. As a sleep-medicine incumbent, it overlaps with Neurosom's clinical-channel go-to-market and could be an acquirer or competitor in sleep diagnostics and therapy.
• Eight Sleep: Eight Sleep makes smart mattresses and sleep pods that regulate temperature to enhance deep sleep. It targets the same consumer sleep-optimization segment as Sleep WISP but uses temperature rather than EEG/TES as its mechanism, making it an adjacent incumbent.
• Oura: Oura's smart ring is the dominant consumer sleep-tracking wearable, with deep sleep staging and recovery metrics. It competes for the same end-user (sleep-conscious consumer / older adults) but does not perform closed-loop stimulation, positioning it as a non-therapeutic tracker.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/91161862
• Xx.com/Neurosom110909
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurosom™